The value of the intrinsic subtypes of breast cancer (luminal A, luminal B, human epidermal growth factor receptor 2 [currently known as ERBB2, but referred to as HER2 in this study]-enriched, and basal-like) in the metastatic setting is currently unknown.
growth factor receptor 2 (currently known as ERBB2, but referred to as HER2 in this study) status, little is known about its biological heterogeneity and effect on patient outcome. This is important because biomarkers that can guide treatment decisions in this setting are urgently needed. 3 The best treatment approach (ie, endocrine therapy vs chemotherapy) in the first-line setting of HR-positive/HER2-negative disease is unknown and the decision today is based on patient characteristics (eg, age), tumor load (eg, number of metastases), type of metastasis (visceral vs bone only), and prior therapy. 3 In contrast to metastatic disease, much effort has been made to elucidate the biological heterogeneity of early breast cancer. 4, 5 During the past 15 years, studies evaluating global gene expression patterns have identified 4 main intrinsic molecular subtypes of breast cancer (luminal A, luminal B, HER2-enriched [HER2E], and basal-like). [6] [7] [8] These entities are associated with distant recurrence and response to endocrine and chemotherapy, even within HR-positive disease. 6, 7, 9 In fact, patients who have clinically HR-positive/HER2-negative disease with a HER2E gene expression profile (which represents roughly 5% of cases) do not seem to respond substantially, as estimated by Ki67 changes, to neoadjuvant endocrine therapy. 10, 11 Although intrinsic profiles are mostly maintained during metastatic progression, 12 their prognostic and predictive value in patients with newly diagnosed HR-positive metastatic disease remains largely unknown. Despite recent advances in the treatment of HR-positive metastatic breast cancer, resistance to endocrine therapies limits their success. 13 Cross-talk between pathways involving the epidermal growth factor family of receptors, epidermal growth factor receptor (EGFR) and HER2, and HRs has been implicated in resistance to endocrine therapy. 2, 14 Lapatinib, a dual tyrosine kinase inhibitor of EGFR and HER2, has improved response rate and median progression-free survival (PFS) in firstline HR-positive breast cancer in combination with letrozole in patients with HER2-positive disease (8.2 vs 3.0 months) but not in those with HER2-negative disease. 15 However, whether patients with HR-positive/HER2-negative disease but with a HER2E gene expression profile benefit from adding lapatinib ditosylate to endocrine therapy is currently unknown.
Here we evaluated, for the first time to our knowledge, the prognostic and predictive value of intrinsic subtypes in tumor samples from EGF30008, a phase 3 randomized clinical trial of endocrine therapy with or without lapatinib in the firstline metastatic setting. 15 
Methods

Patient Data
The eligibility criteria and study design for EGF30008 (NCT00073528) were reported previously. 15, 16 
Gene Expression Analysis
A section of the formalin-fixed paraffin-embedded (FFPE) breast tissue was first examined with hematoxylin-eosin staining to confirm the presence of invasive tumor cells and determine the tumor area. For RNA purification (Roche High Pure FFPET RNA isolation kit), at least 1 to 3 10-μm FFPE slides were used for each tumor specimen, and macrodissection was performed, when needed, to avoid normal breast tissue contamination. 18 A minimum of approximately 150 ng of total RNA was used to measure the expression of 105 breast cancerrelated genes and 5 housekeeping genes using the nCounter platform (Nanostring Technologies). 19 Data were log base 2 transformed and normalized using 5 housekeeping genes (ACTB, MRPL19, PSMC4, RPLP0, and SF3A1). Samples with 10 or fewer counts in at least 50% of the genes were removed. Raw gene expression data will be deposited in Gene Expression Omnibus.
Sample Data and PAM50 Intrinsic Subtyping
Of the 1286 tumor samples, 916 were profiled and 821 met the minimum criteria for further analysis (eFigures 1 and 2 in the Supplement). Intrinsic subtyping (luminal A, luminal B, HER2E, basal-like, and normal-like) was performed using the
Key Points
Question Are the intrinsic subtypes of breast cancer associated with prognosis and lapatinib treatment benefit in patients receiving first-line letrozole for hormone receptor-positive metastatic breast cancer?
Findings In this analysis of 821 tumor samples from the EGF30008 clinical trial, intrinsic subtype was the most important prognostic factor for progression-free survival and overall survival beyond classical clinical-pathological factors, including human epidermal growth factor receptor 2 (currently known as ERBB2, but referred to as HER2 in this study) status. Patients with HER2-enriched tumors within HER2-negative disease benefited from adding lapatinib to letrozole therapy.
Meaning The prognostic information provided by the intrinsic subtypes that further define tumor characteristics might help guide treatment decisions in metastatic breast cancer.
Statistical Analysis
Estimates of PFS and overall survival (OS) were from KaplanMeier curves, and tests of differences used the log-rank test. Univariable and multivariable Cox regression analyses were used to test the independent prognostic significance of each variable. To test the prognostic contribution of the PAM50 subtypes, changes in likelihood ratio (LR) values (χ 2 ) were used to measure and compare the relative amount of additional prognostic information of one variable/score compared with another. To test the predictive value of the PAM50 subtypes, interaction tests between PAM50 subtypes and treatment for PFS were evaluated in univariable and multivariable models. The proportional-hazards assumption was tested on the basis of Schoenfeld residuals. A 2-sided P < .05 was used as the threshold for statistical significance.
Results
Clinical-Pathological Characteristics and Subtype Distribution
The clinical-pathological characteristics of the 821 patients with subtype data were well balanced compared with the patients included in the original study (eTable 1 in the Supplement). The median (range) age was 62 (31-94) years, 700 (86%) of the patients had visceral disease, 644 (80%) had HER2-negative tumors, 157 (20%) had HER2-positive disease, and 602 (73%) had experienced relapse at least 6 months since discontinuation of antiestrogen therapy or not received prior endocrine therapy. Similar to the original results, lapatinib therapy showed a significant PFS benefit in patients with HER2-positive disease but not in those with HER2-negative disease (eFigure 4 in the Supplement).
In both HER2-negative and HER2-positive disease, all breast cancer intrinsic subtypes were identified albeit with different proportions ( Table 1) 
Prognosis Within HER2-Negative Disease
Survival data were available for 644 patients with HER2-negative disease (eFigure 5 in the Supplement). Compared with the luminal A subtype, the other subtypes showed a significantly worse PFS ( Figure 1A ) independently of other clinicalpathological variables ( 
Prognosis Within HER2-Positive Disease
Survival data were available for 157 patients with HER2-positive disease ( Figure 1C ). Compared with the luminal A 
Benefit of Lapatinib Therapy
The effect of lapatinib therapy on PFS in patients with HER2-negative disease was evaluated within each intrinsic subtype ( Figure 2) . Among the different subtypes, only the HER2E Normal-like cases have been excluded in this plot because they are not considered a tumor subtype. 4, 5 The results shown here are regardless of treatment arm (with or without lapatinib). HER2 indicates human epidermal growth factor receptor 2 (currently known as ERBB2, but referred to as HER2 in this study).
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showed a significant benefit from lapatinib therapy in univariate (6.49-month median PFS with lapatinib vs 2.60-month median PFS with placebo; hazard ratio, 0.238 [95% CI, 0.066-0.863]; P = .03) and multivariate (lapatinib vs placebo hazard ratio, 0.040 [95% CI, 0.04-0.395]; P = .006) analyses. The interaction test between HER2E and treatment was significant in univariate (P = .02) and multivariate analyses (P = .006).
The effect of lapatinib on PFS in HER2-positive disease was evaluated within each intrinsic subtype (eFigure 6 in the Supplement). All subtypes seemed to benefit to some degree from lapatinib therapy on the basis of the estimate of the hazard ratio. The interaction tests between each subtype and treatment were not statistically significant (data not shown).
HER2 IHC and FISH in HER2E/HER2-Negative Tumors
Fifty percent (8 of 16) of samples identified in the EGF30008 trial as clinically HER2E/HER2 negative showed either a lack of HER2 expression by IHC or a +1 score (eTable 8 in the Supplement). Determination by FISH in 6 of these samples showed a HER2/CEP17 ratio of 1.6 or less (eTable 9 in the Supplement). Among the other 8 HER2E/HER2-negative cases with an IHC 2+ score, 6 were tested for ERBB2 gene amplification; all showed a HER2/CEP17 ratio of 1.6 or less (eTable 8 in the Supplement). Thus, the HER2E/HER2-negative cases did not show evidence of ERBB2 gene amplification.
Discussion
To our knowledge, this is the first report to evaluate the prognostic and predictive value of breast cancer intrinsic molecular subtypes in postmenopausal patients with HR-positive metastatic disease treated with endocrine therapy with or without lapatinib in the first-line setting. Specifically, our results reveal that (1) all intrinsic molecular subtypes are identified within HER2-negative and HER2-positive diseases, albeit with different proportions; (2) intrinsic subtype is the most important and independent prognostic factor in this setting, even within HER2-positive disease; (3) 95% of patients with luminal A/HER2-negative disease experienced long PFS periods of 14.1 to 19.9 months with letrozole therapy; and (4) patients with HER2E/HER2-negative disease treated with letrozole may benefit from the addition of lapatinib. The optimal systemic treatment strategy for patients with newly diagnosed HR-positive advanced/metastatic breast cancer is currently unknown. National Comprehensive Cancer Network or European School of Oncology-European Society of Medical Oncology second international consensus guidelines for advanced breast cancer 20,21 recommend starting with endocrine therapy but base the decision on clinical parameters such as tumor burden, age, ECOG performance status, disease-free interval, or previous therapies in the adjuvant setting. However, HR-positive disease is clinically and biologically heterogeneous and thus there is an urgent need to identify robust prognostic and/or predictive tumor-based biomarkers to be included with other clinical variables considered in patient management and therapy selection decisions. For example, no predictive biomarker exists to date for novel drugs such as CDK4/6 and phosphatidylinositol 3-kinase/ mammalian target of rapamycin inhibitors that are currently being incorporated earlier in the treatment of HR-positive/ HER2-negative metastatic disease in combination with endocrine therapy. A limited number of studies have evaluated the prognostic value of single pathology-based biomarkers for predicting outcome in the first-line HR-positive metastatic breast cancer setting following endocrine therapy. HER2 indicates human epidermal growth factor receptor 2 (currently known as ERBB2, but referred to as HER2 in this study).
Research Original Investigation Lapatinib Therapy and Subtype in Hormone Receptor-Positive Metastatic Breast Cancer
Nonluminal intrinsic subtypes (ie, HER2E and basal-like) represent 3% to 10% of all HR-positive breast cancers. [6] [7] [8] In patients
with HR-positive disease treated with 5 years of adjuvant tamoxifen only, those with HER2E and basal-like subtypes had poor disease-free survival. 9 Concordant with this finding, both subtypes had the lowest relative decrease in Ki-67 either at 2 weeks or at 4 to 6 months following neoadjuvant endocrine therapy. 10, 11 In terms of chemosensitivity, Jimenez and colleagues 27 recently evaluated the pathological complete response (pCR) rates of the intrinsic subtypes within 180 patients with HR-positive/HER2-negative disease following anthracycline/taxane-based neoadjuvant chemotherapy. Interestingly, patients with HR-positive/ basal-like disease, which represented 7.7% of the population, achieved a pCR rate of 50%, followed by patients with luminal B, HER2E, and luminal A tumors, who achieved a pCR rate of 20%, 14%, and 9%, respectively. Overall, these data, together with our results showing a median PFS of approximately 4.5 months in nonluminal subtypes within HR-positive/HER2-negative disease, suggest that molecular subtype may better represent tumor behavior in the setting of cytotoxic or endocrine therapy than clinical HR assay results. The observation that patients with HER2E/HER2-negative tumors benefit from lapatinib therapy is intriguing. Our prior work has revealed that HER2E/HER2-negative tumors have genomic and genetic alterations similar to those of HER2E/HER2-positive tumors except for the HER2 amplicon, which is only overexpressed/amplified in those HER2E tumors that are HER2 positive.
28 Similar results were obtained in the EGF30008 study when the ERBB2 gene expression was evaluated across the intrinsic subtypes based on clinical HER2 status (eFigure 7 in the Supplement). Thus, the efficacy of lapatinib in the group of patients with HER2-negative/HER2E disease might be due to EGFR inhibition rather than HER2 inhibition, although this will require further investigation. The present study has several limitations. First, this is an unplanned retrospective analysis of a prospective clinical trial.
To minimize bias, we were able to profile almost 2 out of 3 tumor samples from the original population, and this subset had a similar distribution of clinical-pathological variables and a similar outcome behavior to the original study population. In addition, the laboratory that performed and reported the gene expression results for each sample was blinded to clinical data. Second, almost all profiled samples from this data set come from primary tumors rather than metastatic tumor. Although we cannot predict what the findings would have been if the analysis had been done on metastatic samples only, the reality is that metastatic tissues are not always available in clinical practice and thus a biomarker derived from primary tumors is of value, especially if this biomarker remains stable during tumor progression such as the intrinsic subtypes.
12 However, further studies are needed to determine the concordance of intrinsic subtyping in primary vs metastatic tissues and the stability of subtype during or after therapy. Finally, in the EGF30008 clinical study, HER2 testing was performed by a high-volume, commercial laboratory to determine HER2 status using standardized testing methods in a single laboratory. Additionally, HER2 status was evaluated by an academic reference laboratory in a limited number of cases from the EGF30008 study population, revealing 93% concordance (eTable 10 in the Supplement).
16,17
Conclusions
Hormone receptor-positive disease is biologically heterogeneous and intrinsic subtypes are associated with outcome in a first-line metastatic setting. Patients with HR-positive/HER2-negative disease with a HER2E profile may benefit from lapatinib therapy. The clinical value of intrinsic subtyping in HR-positive metastatic breast cancer warrants further investigation, but patients with luminal A/HER2-negative metastatic disease might be good candidates for letrozole monotherapy in the first-line setting regardless of visceral disease and number of metastases, whereas patients with HER2E/ HER2-negative or basal-like/HER2-negative subtypes need other treatment strategies such as chemotherapy or novel targeted drugs. 
